Sonoma Pharmaceuticals, Inc.
SNOA
$2.72
$0.730136.69%
| Weiss Ratings | SNOA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | SNOA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | SNOA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.49 | |||
| Price History | SNOA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 24.55% | |||
| 30-Day Total Return | -3.52% | |||
| 60-Day Total Return | -6.48% | |||
| 90-Day Total Return | -8.36% | |||
| Year to Date Total Return | 2.24% | |||
| 1-Year Total Return | -11.04% | |||
| 2-Year Total Return | -87.20% | |||
| 3-Year Total Return | -95.19% | |||
| 5-Year Total Return | -97.27% | |||
| 52-Week High % Change | -78.77% | |||
| 52-Week Low % Change | 4.74% | |||
| Price | SNOA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $9.37 | |||
| 52-Week Low Price | $1.90 | |||
| 52-Week Low Price (Date) | Mar 07, 2025 | |||
| 52-Week High Price (Date) | Jul 11, 2024 | |||
| Valuation | SNOA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 3.22M | |||
| Enterprise Value | -1.90M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -3.96 | |||
| Earnings Per Share Growth | -79.40% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.21 | |||
| Price/Book (Q) | 0.66 | |||
| Enterprise Value/Revenue (TTM) | -0.14 | |||
| Price | $2.74 | |||
| Enterprise Value/EBITDA (TTM) | 0.44 | |||
| Enterprise Value/EBIT | 0.43 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | SNOA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 1.46M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | SNOA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 800 759 9305 | |||
| Address | 5445 Conestoga Court Boulder, CO 80301 | |||
| Website | sonomapharma.com | |||
| Country | United States | |||
| Year Founded | 1999 | |||
| Profitability | SNOA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -31.94% | |||
| Profit Margin | -26.82% | |||
| Management Effectiveness | SNOA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -19.72% | |||
| Return on Equity | -- | |||
| Income Statement | SNOA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 13.97M | |||
| Total Revenue (TTM) | 13.97M | |||
| Revenue Per Share | $9.54 | |||
| Gross Profit (TTM) | 5.03M | |||
| EBITDA (TTM) | -4.32M | |||
| EBIT (TTM) | -4.46M | |||
| Net Income (TTM) | -3.75M | |||
| Net Income Avl. to Common (TTM) | -3.75M | |||
| Total Revenue Growth (Q YOY) | 13.58% | |||
| Earnings Growth (Q YOY) | -7.16% | |||
| EPS Diluted (TTM) | -3.96 | |||
| EPS Diluted Growth (Q YOY) | 60.03% | |||
| Balance Sheet | SNOA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 5.24M | |||
| Cash Per Share (Q) | $3.58 | |||
| Total Current Assets (Q) | 12.38M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 4.87M | |||
| Current Ratio (Q) | 3.343 | |||
| Book Value Per Share (Q) | $3.01 | |||
| Total Assets (Q) | 13.67M | |||
| Total Current Liabilities (Q) | 3.70M | |||
| Total Debt (Q) | 119.00K | |||
| Total Liabilities (Q) | 8.80M | |||
| Total Common Equity (Q) | 4.87M | |||
| Cash Flow | SNOA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -15.00K | |||
| Cash from Financing (TTM) | 3.41M | |||
| Net Change in Cash (TTM) | 2.83M | |||
| Levered Free Cash Flow (TTM) | 1.25M | |||
| Cash from Operations (TTM) | 159.00K | |||
